Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2)

被引：0
|
作者：
Mease, P. [1 ,2 ]
Kirkham, B. [3 ]
McInnes, I. B. [4 ]
Kremer, J. [5 ,6 ]
Kandala, S. [7 ]
Pricop, L. [8 ]
Mpofu, S. [9 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Guys & St Thomas NHS Fdn Trust, London, England
[4] Univ Glasgow, Glasgow, Lanark, Scotland
[5] Albany Med Coll, Albany, NY 12208 USA
[6] Ctr Rheumatol, New York, NY USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, Orange, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P115
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [31] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    Van der Heijde, Desiree
    Landewe, Robert
    Conaghan, Philip G.
    Gottlieb, Alice B.
    Richards, Hanno
    Pricop, Luminita
    Ligozio, Gregory
    Patekar, Manmath
    Mpofu, Shephard
    LANCET, 2015, 386 (9999): : 1137 - 1146
  • [32] Efficacy and safety of ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: Results from 2 phase 3, multicenter, double-blind, placebo-controlled study
    Kavanaugh, Arthur
    Puig, Lluis
    Gottlieb, Alice B.
    Ritchlin, Christopher
    You, Yin
    Li, Shu
    Song, Michael
    Randazzo, Bruce
    Rahman, Proton
    McInnes, Iain B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S12 - S12
  • [33] Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study
    Coates, Laura C.
    Mease, Philip J.
    Gossec, Laure
    Kirkham, Bruce
    Sherif, Bintu
    Gaillez, Corine
    Mpofu, Shephard
    Jugl, Steffen M.
    Karyekar, Chetan
    Gandhi, Kunal K.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (10) : 1529 - 1535
  • [34] Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study.
    Kavanaugh, Arthur
    McInnes, Iain B.
    Gottlieb, Alice B.
    Puig, Lluis
    Rahman, Proton
    Ritchlin, Christopher T.
    Li, Shu
    Wang, Yuhua
    Doyle, Mittie K.
    Mendelsohn, Alan M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4168 - 4168
  • [35] EFFECT OF SECUKINUMAB ON SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS OF A 24-WEEK MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    McInnes, Iain
    Sieper, Joachim
    Braun, Juergen
    Emery, Paul
    van der Heijde, Desiree
    Isaacs, John
    Dahmen, Georg
    Wollenhaupt, Juergen
    Schulze-Koops, Hendrik
    Gsteiger, Sandro
    Bertolino, Arthur
    Hueber, Wolfgang
    Tak, Paul P.
    RHEUMATOLOGY, 2012, 51 : 90 - 91
  • [36] EFFICACY AND SAFETY OF USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS WITH SPONDYLITIS AND PERIPHERAL JOINT INVOLVEMENT: RESULTS FROM A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Kavanaugh, A.
    Puig, L.
    Gottlieb, A. B.
    Ritchlin, C.
    You, Y.
    Wang, Y.
    Mendelsohn, A. M.
    Song, M.
    Rahman, P.
    McInnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 136 - 136
  • [37] LACK OF EFFECT OF SECUKINUMAB TREATMENT ON THE LIPID PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY
    Durez, P.
    Genovese, M.
    Kellner, H.
    Codding, C.
    Ligozio, G.
    Richards, H.
    Escrig, C.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 194 - 195
  • [38] Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
    Blanco, Francisco J.
    Moericke, Ruediger
    Dokoupilova, Eva
    Codding, Christine
    Neal, Jeffrey
    Andersson, Mats
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (06) : 1144 - 1153
  • [39] A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results
    Idowu, Modupe
    Otieno, Lucas
    Dumitriu, Bogdan
    Lobo, Clarisse L. C.
    Thein, Swee Lay
    Andemariam, Biree
    Nnodu, Obiageli E.
    Inati, Adlette
    Glaros, Alexander K.
    Olalla Saad, Sara Teresinha
    Bartolucci, Pablo
    Colombatti, Raffaella
    Taher, Ali T.
    Abboud, Miguel R.
    Oluyadi, Abdulafeez
    Iyer, Varsha
    Yin, Ophelia
    Morris, Susan
    Yates, Amber M.
    Shao, Hui
    Patil, Spurthi
    Urbstonaitis, Rolandas
    Zaidi, Ahmar U.
    Smith, Wally R.
    BLOOD, 2023, 142
  • [40] Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
    Hasan Tahir
    Atul Deodhar
    Mark Genovese
    Tsutomu Takeuchi
    Jacob Aelion
    Filip Van den Bosch
    Sibylle Haemmerle
    Hanno B. Richards
    Rheumatology and Therapy, 2017, 4 : 475 - 488
12345